KRAS mutant lung adenocarcinoma patients with concurrent inactivating mutations in the tumor suppressor genes of KEAP1 and STK11 have demonstrated lower clinical response rates treated with standard chemotherapy or immunotherapies [30,106]. This evidence concerns the gene STK11 and lung adenocarcinoma.